Vertex
Vertex is a Massachusetts-based biotechnology company that develops and commercializes medicines for the treatment of cystic fibrosis and sickle cell diseases.
Business Model:
Revenue: $8.7B
Employees: 1,001-5,000
Industries / Tags:
Detailed Vertex Information
Geographic Data
Address: 50 Northern Avenue
City: Boston
State: MA
Zip: 02210
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$50M
Raised Total:$443M
Social
Metrics
439,856Website Global Rank
115,324Website Monthly Traffic
Twitter Followers
Description
Vertex is a Massachusetts-based biotechnology company that develops and commercializes medicines for the treatment of cystic fibrosis and sickle cell diseases.
Contact Phone:
+16173416100
Contact Email:
Vertex went public on 7/25/1991 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
7/25/1991
Ticker Symbol:
VRTX
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 12/2018 | Genomics | Series B | 9.1M |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 8/2018 | Genomics | Series B | 32.5M |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 3/2020 | Kymera Therapeutics | Series C | 0 |
| 12/2018 | Genomics | Series B | 0 |
| 8/2018 | Genomics | Series B | 0 |
| 4/2015 | CRISPR Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2022 | Post-IPO Equity | $50M | 3/2009 | Post-IPO Equity | $2.4M | 7/1989 | Venture Round | 4 | $5.8M |
Norwest Venture Partners J.H. Whitney &a; Co New Enterprise Associates Greylock Norwest Venture Partners J.H. Whitney &a; Co New Enterprise Associates Greylock |
9/2009 | Post-IPO Equity | 1 | $35M |
Janssen Belgium Janssen Belgium Janssen Belgium Janssen Belgium |
12/2009 | Post-IPO Equity | 4 | $443M |
J.P. Morgan Securities Inc. Bank of America Merrill Lynch Morgan Stanley Goldman Sachs J.P. Morgan Securities Inc. Bank of America Merrill Lynch Morgan Stanley Goldman Sachs |
9/2009 | Post-IPO Debt | $120M |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 7/2022 | ViaCyte | |
| 3/2022 | Vectrus | |
| 9/2019 | Semma Therapeutics | |
| 6/2019 | Exonics Therapeutics | |
| 4/2001 | Aurora Biosciences Corporation |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
